Claims to Cover Therapeutic Delivery Across Blood-Brain Barrier
NOVATO, Calif., April 29 /PRNewswire-FirstCall/ — Raptor Pharmaceuticals Corp. (“Raptor” or the “Company”) (OTC Bulletin Board: RPTP) today announced that the United States Patent and Trademark Office (“USPTO”) has issued two Notices of Allowance for U.S. Patent Application Nos. 10/812,849 and 11/202,566, titled “Methods of increasing delivery of active agents to brain comprising administering receptor-associated protein (“RAP”) fragments conjugated to active agents.”
(Logo: http://www.newscom.com/cgi-bin/prnh/20071022/NYM074LOGO)
The newly allowed claims relate to Raptor’s NeuroTrans(TM) platform and generally cover the use of its proprietary RAP peptides in the delivery of diagnostic and therapeutic agents across the BBB into the central nervous system (“CNS”). The claims broadly encompass all neurological disorders, including Alzheimer’s Disease, Huntington’s Disease, Parkinson’s Disease, Multiple Sclerosis, and Amytrophic Lateral Sclerosis. We expect the official patents to issue in 2009, and if they do, will have a preliminary patent term that expires in 2023.
NeuroTrans(TM) has been designed to deliver drugs across the BBB in a minimally invasive way by conjugating them to RAP peptides engineered by Raptor. Hundreds of neurodegenerative disorders are ineffectively treated because most drugs are unable to penetrate the BBB and deliver a therapeutic effect. The development of effective brain targeting and delivery technologies, such as NeuroTrans(TM), has the potential to address the challenges involved in treating many of these CNS disorders.
Christopher M. Starr, Ph.D., Raptor’s Chief Executive Officer and Co-Founder, commented, “We are pleased that the USPTO has allowed pivotal claims that may offer strong
Latest Comments